One-stage radical cystectomy for bladder carcinoma: operative mortality, cost/benefit analysis.
An analysis of cystectomies performed between September 1, 1969 and December 31, 1974 was conducted to determine the rates of morbidity (59 per cent) and operative mortality (4.1 per cent). Comparison of these figures for single operations with data published from other sources concerning staging of the therapeutic procedures suggests that there is no benefit for the patient relative to surgical morbidity or mortality if the latter course is followed. Conversely, prolongation of hospital experience, multiple operations, absence from productive activity and increased health care cost are associated with the staged procedures. Application of cost/benefit analysis suggests that this experience may act as a model to evaluate competing forms of therapy involving other disorders. When costs are not equivalent and benefits are the same the more expensive form of therapy should not be offered except for unusual circumstances.
D000328:Adult; D000368:Aged; D054598:Blue Cross Blue Shield Insurance Plans; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005260:Female; D006801:Humans; D007348:Insurance, Health; D007349:Insurance, Health, Reimbursement; D007902:Length of Stay; D008297:Male; D008404:Massachusetts; D006278:Medicare; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality; D013514:Surgical Procedures, Operative / Q000191:economics / Q000401:mortality*; D001743:Urinary Bladder / Q000601:surgery*; D001749:Urinary Bladder Neoplasms / Q000601:surgery*; D014547:Urinary Diversion